175205-33-1 Usage
Uses
Used in Organic Synthesis:
2-(TRIFLUOROMETHOXY)PHENYL ISOTHIOCYANATE is used as a reagent in organic synthesis for the preparation of various biologically active molecules. Its unique structure and functional group make it a valuable building block for the synthesis of complex organic compounds.
Used in Pharmaceutical Industry:
2-(TRIFLUOROMETHOXY)PHENYL ISOTHIOCYANATE is used as a key intermediate in the development of pharmaceuticals due to its potential to contribute to the creation of new drugs with enhanced properties.
Used in Agrochemical Industry:
2-(TRIFLUOROMETHOXY)PHENYL ISOTHIOCYANATE is used as a precursor in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Medicinal Chemistry Research:
2-(TRIFLUOROMETHOXY)PHENYL ISOTHIOCYANATE is used as a chemical for research and development in medicinal chemistry, particularly for its antiproliferative and antifungal activities, which make it an important candidate for the discovery of new therapeutic agents.
Used in Pharmaceutical Sciences:
2-(TRIFLUOROMETHOXY)PHENYL ISOTHIOCYANATE is utilized in pharmaceutical sciences for its potential applications in drug discovery and development, given its promising biological activities and its role in the synthesis of complex organic compounds with therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 175205-33-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,2,0 and 5 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 175205-33:
(8*1)+(7*7)+(6*5)+(5*2)+(4*0)+(3*5)+(2*3)+(1*3)=121
121 % 10 = 1
So 175205-33-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H4F3NOS/c9-8(10,11)13-7-4-2-1-3-6(7)12-5-14/h1-4H
175205-33-1Relevant academic research and scientific papers
TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
-
Page/Page column 55; 56, (2012/06/01)
This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
-
, (2012/12/13)
This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds
Kai, Hiroyuki,Morioka, Yasuhide,Tomida, Minoru,Takahashi, Tadashi,Hattori, Maki,Hanasaki, Kohji,Koike, Katsumi,Chiba, Hiroki,Shinohara, Shunji,Kanemasa, Toshiyuki,Iwamoto, Yuka,Takahashi, Kohji,Yamaguchi, Yoshitaka,Baba, Takahiko,Yoshikawa, Takayoshi,Takenaka, Hideyuki
, p. 3925 - 3929 (2008/02/11)
Structure-activity relationships and efforts to optimize the pharmacokinetic profile of a class of 2-arylimino-5,6-dihydro-4H-1,3-thiazines as cannabinoid receptor agonists are described. Among the compounds examined, compound 14 showed potent affinity and high selectivity for CB2, and compound 23 showed potent affinities against CB1 and CB2. These compounds displayed oral bioavailability.
